BioSpace News Archive

Neuronetics, Inc. announced that participating providers of its NeuroStar® Advanced Therapy treatment for depression are offering complimentary consultations during National Depression Awareness Month.

Prince Sultan Cardiac Center Al Hassa, one of the premier cardiac centers in Saudi Arabia, is the first hospital in the Middle East to be awarded Global Healthcare Accreditation’s Certification of Conformance with COVID-19 Guidelines for Medical Travel Programs.

Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces the upcoming presentation of results from a prospective study using its Target Selector™ testing of the cerebrospi

BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced it has closed the acquisition of SciSafe

$3.36 million Commercialization Readiness Pilot award from the National Institute on Aging for completing the development of CogniMIR™, a blood-based test for early detection of mild cognitive impairment and Alzheimer’s disease

Certara, a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has again renewed and expanded its licenses of Certara’s biosimulation software, with more than 400 user licenses of Simcyp™ and Phoenix™ platforms. Eleven divisions and offices of the FDA use Certara’s software for internal resea

United Health Products, Inc. announced that it has submitted documents requested by the FDA in conjunction with its PMA application to use HemoStyp in internal surgeries.

Halberd Corporation announced they have obtained world-wide license to a provisional patent application covering a nasal spray to be used as a prevention measure against coronavirus.

Align Technology, Inc. (Nasdaq: ALGN) announced today that the Company will report third quarter 2020 financial results on Wednesday, October 21, 2020, after the close of market. Financial results will be released at 4:00 p.m. ET (1:00 p.m. PT) and will be available on the Investor Relations section of the Company’s website at http://investor.aligntech.com . Following the press release, the Company will host a conference call to discuss it

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in the Jefferies Virtual Cell Therapy Summit in October 2020. Jefferies Virtual Cell Therapy Summit Tuesday, October 6, 2020 12:30 PM PT/3:30 PM ET This webcast will be made available on the Company’s website at w